UK patients get early access to AbbVie’s hepatitis regimen
AbbVie’s glecaprevir/pibrentasvir (G/P) has become the first treatment for chronic hepatitis C to be included in the UK’s Early Access to Medicines Scheme (EAMS).
Read More
Tag: G/P
AbbVie reports 99% cure rate for pan-genotypic Hep C therapy
AbbVie has released late-stage clinical data showing high cure rates for its experimental ribavirin-free hepatitis C therapy glecaprevir/pibrentasvir (G/P) across the majority of patients infected with the virus.
Read More
